Silexion Therapeutics shares are trading lower. The company announced the submission of a Clinical Trial Application to Germany for its planned Phase 2/3 clinical trial of its lead, siRNA product candidate, SIL204.

Benzinga Newsdesk www.benzinga.com Negative 55.3%

Neg 55.3% Neu 0% Pos 0%

Comments

No comments yet. Be the first!